Polygonum multiflorum / Fo-ti-tieng
Fo-ti is native to central and southern China and is distributed in Japan and Taiwan. It is a perennial climbing herb, which can grow to 30 feet in height. The plant has red stems, heart-shaped leaves and white or pink flowers. The roots of 3- to 4-year-old plants are dried in autumn. The stems and leaves are used also. 1 , 2
Fo-ti is a popular Chinese tonic herb, dating back to 713 A.D. 1 It is considered one of the country's great four herbal tonics (along with angelica, lycium and panax). 3 Regarded as a rejuvenating plant, fo-ti has been thought to prevent aging and to promote longevity. According to folklore, the older and larger roots have the most power. 1 One source quotes “...300-year-old (root) product makes one immortal.” 3
Fo-ti contains chrysophanic acid, chrysophanic acid anthrone and chrysophanol. Anthraquinones emodin and rhein are also present. Lecithin has also been found in the plant. 1 , 3 A stilbene glucoside from fo-ti has been identified. 4 A spectrophotometric assay of stilbene glucoside in another report may be used for quality control in the plant's processing. 5 Qualitative analysis and content determination of phospholipids in fo-ti drug vs four processed products have been performed. 6 An alcoholic extract from fo-ti roots yielded three bioactive compounds: E-2,3,5,4′-tetrahydroxystilbene, 2-O-beta-D-glucopyranoside and cis- and trans-E-3-butylidene-4,5,6,7-tetrahydro-6,7-dihydroxy-1(3H)-isobenzofuranone. Two of these compounds were found to be calcium-ATPase inhibitors. 7
Fo-ti Uses and Pharmacology
Rejuvenating and toning properties
In China, millions take fo-ti regularly for its rejuvenating and toning properties. It is used to increase liver and kidney function and to cleanse the blood. The plant is also prescribed for symptoms of premature aging such as gray hair. 1
A Chinese-13-herb mixture (“shou xing bu zhi”) that includes fo-ti has been studied for its antisenility effects in mice. Results showed this mixture was effective in slowing the aging process. 8 It is also indicated for insomnia, weak bones, constipation and atherosclerosis. 2 Lifespan and lipid studies of fo-ti in quails have been performed. 9 Fo-ti also has been shown to reduce blood cholesterol levels in animals. 1 The root portion of the plant has exhibited an inhibitory effect on triglyceride accumulation and has reduced enlargement of mice livers. 10
In a clinical trial in humans, fo-ti had similar cholesterol-lowering effects. 1
Emodin exhibited vasodilation and immunosuppressive effects in rats, suggesting its usefulness against transplantation rejection and autoimmune disease. Extract of he shou wu significantly reduced tumor incidence in rats in another report. 11 The Chinese use the root of the plant for cancer as well. 3
Stilbenes isolated from polygonum species have been evaluated on rat peritoneal polymorphonuclear leukocyte lipoxygenase and cyclooxygenase activity. 12 A mixture including fo-ti has been studied for its effects on glucocorticoid receptor in senile rat thymocyte. 13 The plant has also been shown to inhibit lipid peroxidation in isolated rat heart mitochondria. 14 Fo-ti also exhibits antimicrobial properties against mycobacteria and malaria. 1
Other uses of the plant include: To increase fertility, 1 to increase blood sugar levels, 1 to treat anemia and to relieve muscle aches. 3
Fo-ti is used at daily doses of 9 to 15 g of raw herb; however, there do not appear to be any clinical studies supporting this dosage.
Information regarding safety and efficacy in pregnancy and lactation is lacking.
None well documented.
One case report describes herb-induced hepatitis in a 31-year-old pregnant Chinese woman from medicine prepared from the plant. 15 The use of these compounds in pregnant women should be discouraged.
There is little information in the area of toxicology from fo-ti. However, all plants that contain anthraquinone cathartic compounds should be used cautiously to prevent developing dependence on their laxative effects.
1. Chevallier A. Encyclopedia of Medicinal Plants . New York, NY: DK Publishing, 1996;121.
2. Reid D. Chinese Herbal Medicine . Boston, MA: Shambhala Publishing, Inc., 1994;150.
3. Duke J. CRC Handbook of Medicinal Herbs . Boca Raton, FL: CRC Press, Inc., 1989;163-164.
4. Hata K, et al. Yakugaku Zasshi . 1975;95:211-213.
5. Liu C, et al. Chung Kuo Chung Yao Tsa Chih . 1991;16:469-472.
6. Ma C, et al. Chung Kuo Chung Yao Tsa Chih . 1991;16:662-664.
7. Grech J, et al. J Nat Prod . 1994;57:1682-1687.
8. Chen J. Chung Hsi I Chieh Ho Tsa Chih . 1989;9:226-227.
9. Wang W, et al. Chung Hsi I Chieh Ho Tsa Chih . 1988;8:223-224.
10. Liu C, et al. Chung Kuo Chung Yao Tsa Chih . 1992;17:595-596.
11. Horikawa K, et al. Mutagenesis . 1994;9:523-526.
12. Kimura Y, et al. Biochim Biophys Acta . 1985;834:275-278.
13. Zhao W, et al. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih . 1995;15:92-94.
14. Hong, et al. Am J Chin Med . 1994;22:63-70.
15. But P, et al. Vet Hum Toxicol . 1996;38:280-282.
Polygonum multiflorum Thunb. (PMT, Polygonaceae family, Figure 1)), well known as He shou wu in China and Fo-ti in North America, is one of the most popular perennial Chinese traditional medicinal vine-like herbs, officially listed in the Chinese Pharmacopoeia. Various parts of the plants were utilized for different medicinal purposes. The leaves [Figure 2a], root tuber [Figure 2b] and rhizomes [Figure 2c] of this plant have been used as tonic and anti-aging agents[7,8,9,10,11,12] whereas the stem [Figure 2d] is used to alleviate insomnia and even to have an antidiabetic therapeutic activity as well.[13,14,15]
Laboratory studies and clinical practice have demonstrated that PMT possesses various biological and therapeutic actions, including anti-tumor,[16,17] antibacterial, anti-inflammatory, anti-oxidant,[19,20,21] anti-HIV, liver protection,[23,24] nephroprotection, antidiabetic,[15,26] anti-alopecia,[27,28] and anti-atherosclerotic activities.[29,30] It has been also reported to exert preventive activity against neurodegenerative diseases,[31,32,33,34,35] cardiovascular diseases and to reduce hyperlipidemia as well.[36,37]
The clinical efficacy, as well as the safety of PMT and its bioactive products, has attracted much attention in the recent years; due to the increasing reports of various cases on hepatotoxicity,[38,39,40,41,42] published worldwide. In the present review, the advancements in thorough investigation of clinical studies and pharmacokinetics (PKs)-pharmacodynamics (PDs) profile of P. multiflorum are discussed, meanwhile describing the clinical features of this particular herbal-induced liver injury. This report will enlighten the broad understanding on the clinical therapeutic evaluation of PMT or other herbal drug containing quite the same phytochemical components.
1. Taylor JL, Rabe T, McGraw LJ, Jäger AK, van Staden J. Towards the scientific validation of traditional medicinal plants. Plant Growth Regul. 2001;34:23–37.
2. Wachtel-Galor S, Benzie IF, editors. Herbal Medicine: Biomelecular and Clinical Aspect. 2nd ed. Florida: CRC Press; 2011. Herbal medicine: An introduction to its history, usage, regulation, current trends, and research needs; pp. 1–10. [PubMed]
3. Abolaji OA, Adebayo AH, Odesanmi OS. Nutritional qualities of three medicinal plants parts (Xylopia aethiopica, Blighia sapida and Parinari polyandra) commonly used by pregnant women in the western part of Nigeria. Pak J Nutr. 2007;6:655–8.
4. Hamburger M, Hostettman K. Bioactivity in plants: The link between phytochemistry and medicine. Phytochemistry. 1991;30:3864–74.
5. Lv L, Shao X, Wang L, Huang D, Ho CT, Sang S. Stilbene glucoside from Polygonum multiflorumThunb.: A novel natural inhibitor of advanced glycation end product formation by trapping of methylglyoxal. J Agric Food Chem. 2010;58:2239–45. [PubMed]
6. 1st Div. Beijing: China Chemical Industry Press; 2010. Pharmacopoeia Commission of the Ministry of Health. Pharmacopoeia of the People's Republic of China (PPRC) pp. 22–3.
7. Grech JN, Li Q, Roufogalis BD, Duck CC. Novel Ca (2+)-ATPase inhibitors from the dried root tubers of Polygonum Multiflorum. J Nat Prod. 1994;57:1682–7. [PubMed]
8. Kam JK. Mutagenic activity of Ho Shao Wu (Polygonum multiflorum Thunb) Am J Chin Med. 1981;9:213–5. [PubMed]
9. Um MY, Choi WH, Aan JY, Kim SR, Ha TY. Protective effect of Polygonum multiflorum Thunb on amyloid beta-peptide 25–35 induced cognitive deficits in mice. J Ethnopharmacol. 2006;104:144–8.[PubMed]
10. Kwon BM, Kim SH, Baek NI, Lee SI, Kim EJ, Yang JH, et al. Farnesyl protein transferase inhibitory components of Polygonum multiflorum. Arch Pharm Res. 2009;32:495–9. [PubMed]
11. Yang LJ. Inssussion on the application of hair-blackening and hair growth accelerating effects of Polygonum multiflorum from ancient prescription. J Tradit Chin Med. 2008;7:39–40.
12. Guan S, Su W, Wang N, Li P, Wang Y. Effects of radix polygoni multiflori components on tyrosinase activity and melanogenesis. J Enzyme Inhib Med Chem. 2008;23:252–5. [PubMed]
13. Cha DS, Jeon H. Anti-inflammatory effect of MeOH extracts of the stem of Polygonum multiflorum in LPS-stimulated mouse peritoneal macrophages. Nat Prod Sci. 2009;15:83–9.
14. Chen FP, Jong MS, Chen YC, Kung YY, Chen TJ, Chen FJ, et al. Prescriptions of Chinese herbal medicines for insomnia in Taiwan during 2002. Evid Based Complement Alternat Med. 2011;2011:236341.[PMC free article] [PubMed]
15. Wang H, Song L, Feng S, Liu Y, Zuo G, Lai F, et al. Characterization of proanthocyanidins in stems of Polygonum multiflorum Thunb as strong starch hydrolase inhibitors. Molecules. 2013;18:2255–65.[PubMed]
16. Horikawa K, Mohri T, Tanaka Y, Tokiwa H. Moderate inhibition of mutagenicity and carcinogenicity of benzo[a] pyrene, 1,6-dinitropyrene and 3,9-dinitrofluoranthene by Chinese medicinal herbs. Mutagenesis. 1994;9:523–6. [PubMed]
17. Choi SG, Kim J, Sung ND, Son KH, Cheon HG, Kim KR, et al. Anthraquinones, Cdc25B phosphatase inhibitors, isolated from the roots of Polygonum multiflorum Thunb. Nat Prod Res. 2007;21:487–93.[PubMed]
18. Zuo GY, Wang GC, Zhao YB, Xu GL, Hao XY, Han J, et al. Screening of Chinese medicinal plants for inhibition against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) J Ethnopharmacol. 2008;120:287–90. [PubMed]
19. Ip SP, Tse AS, Poon MK, Kow KM, Ma CY. Antioxidant activities of Polygonum multiflorum Thunb. in vivo and in vitro. Phytother Res. 1997;11:42–4.
20. Chan YC, Wang MF, Chen YC, Yang DY, Lee MS, Cheng FC. Long-term administration of Polygonum multiflorum Thunb. reduces cerebral ischemia-induced infarct volume in gerbils. Am J Chin Med. 2003;31:71–7. [PubMed]
21. Lv LS, Gu XH, Tang J, Ho CT. Antioxidant activity of stilbene glycoside from Polygomum multiflorum Thunb. in vivo. Food Chem. 2007;104:1678–81.
22. Lin HW, Sun MX, Wang YH, Yang LM, Yang YR, Huang N, et al. Anti-HIV activities of the compounds isolated from Polygonum cuspidatum and Polygonum multiflorum. Planta Med. 2010;76:889–92. [PubMed]
23. Lee BH, Huang YY, Duh PD, Wu SC. Hepatoprotection of emodin and Polygonum multiflorum against CCl (4)-induced liver injury. Pharm Biol. 2012;50:351–9. [PubMed]
24. Huang CH, Horng LY, Chen CF, Wu RT. Chinese herb Radix Polygoni Multiflori as a therapeutic drug for liver cirrhosis in mice. J Ethnopharmacol. 2007;114:199–206. [PubMed]
25. Guo XH, Liu ZH, Dai CS, Li H, Liu D, Li LS. Rhein inhibits renal tubular epithelial cell hypertrophy and extracellular matrix accumulation induced by transforming growth factor beta1. Acta Pharmacol Sin. 2001;22:934–8. [PubMed]
26. Li CR, Cai F, Yang YQ, Zhao XY, Wang C, Li J, et al. Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: Involvement of SIRT1 and TGF-β1 pathway. J Ethnopharmacol. 2010;649:382–9. [PubMed]
27. Park HJ, Zhang N, Park DK. Topical application of Polygonum multiflorum extract induces hair growth of resting hair follicles through upregulating Shh and ß-catenin expression in C57BL/6 mice. J Ethnopharmacol. 2011;135:369–75. [PubMed]
28. Seo SR, Kang G, Ha JW, Kim JC. In vivo hair growth-promoting efficacies of herbal extracts and their cubosomal suspensions. J Ind Eng Chem. 2013;19:1331–9.
29. Yang PY, Almofti MR, Lu L, Kang H, Zhang J, Li TJ, et al. Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum. J Pharmacol Sci. 2005;99:294–300. [PubMed]
30. Zhang YZ, Shen JF, Xu JY, Xiao JH, Wang JL. Inhibitory effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside on experimental inflammation and cyclooxygenase 2 activity. J Asian Nat Prod Res. 2007;9:355–63. [PubMed]
31. Li X, Matsumoto K, Murakami Y, Tezuka Y, Wu Y, Kadota S. Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice. Pharmacol Biochem Behav. 2005;82:345–52. [PubMed]
32. Zhang L, Xing Y, Ye CF, Ai HX, Wei HF, Li L. Learning-memory deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by using tetrahydroxystilbene glucoside. Behav Brain Res. 2006;173:246–54. [PubMed]
33. Wang R, Tang Y, Feng B, Ye C, Fang L, Zhang L, et al. Changes in hippocampal synapses and learning-memory abilities in age-increasing rats and effects of tetrahydroxystilbene glucoside in aged rats. Neuroscience. 2007;149:739–46. [PubMed]
34. Liu LF, Durairajan SS, Lu JH, Koo I, Li M. In vitro screening on amyloid precursor protein modulation of plants used in Ayurvedic and traditional Chinese medicine for memory improvement. J Ethnopharmacol. 2012;141:754–60. [PubMed]
35. Zhang L, Huang L, Chen L, Hao D, Chen J. Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease. Toxicol Lett. 2013;222:155–63. [PubMed]
36. Liu QL, Xiao JH, Ma R, Ban Y, Wang JL. Effect of 2,3,5,4'- tetrahydroxystilbene-2-O-beta-D-glucoside on lipoprotein oxidation and proliferation of coronary arterial smooth cells. J Asian Nat Prod Res. 2007;9:689–97. [PubMed]
37. Xie W, Zhao Y, Du L. Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia. J Ethnopharmacol. 2012;140:345–67. [PubMed]
38. Park GJ, Mann SP, Ngu MC. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J Gastroenterol Hepatol. 2001;16:115–7. [PubMed]
39. Mazzanti G, Battinelli L, Daniele C, Mastroianni CM, Lichtner M, Coletta S, et al. New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum. Ann Intern Med. 2004;140:W30. [PubMed]
40. Panis B, Wong DR, Hooymans PM, De Smet PA, Rosias PP. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation. J Pediatr Gastroenterol Nutr. 2005;41:256–8. [PubMed]
41. Cárdenas A, Restrepo JC, Sierra F, Correa G. Acute hepatitis due to shen-min: A herbal product derived from Polygonum multiflorum. J Clin Gastroenterol. 2006;40:629–32. [PubMed]
42. Cho HC, Min HJ, Ha CY, Kim HJ, Kim TH, Jung WT, et al. Reactivation of Pulmonary Tuberculosis in a Patient with Polygonum multiflorum Thunb-Induced Hepatitis. Gut Liver. 2009;3:52–6. [PMC free article][PubMed]
43. Ebadi MS, editor. Pharmacodynamic Basis of Herbal Medicine. 2nd ed. Boca Raton, Flordia: CRC Press, Taylor and Francis; 2007. Herb-drug interactions; pp. 37–46.
44. Beelen AP, Lewis LD. Clinical pharmacology overview. In: Figg WD, McLeod HL, editors. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. New Jersey: Humana Press; 2004. pp. 111–28.
45. Berliocchi L, Russo R, Mizoguchi H, Corasaniti MT. Mechanisms and clinical relevance of herb-drug interactions from the perspectives of pharmacokinetics. In: Bagetta G, Cosentino M, Corasaniti MT, Sakurada S, editors. Herbal Medicines: Development and Validation of Plant-Derived Medicines for Human Health. Florida: CRC Press; 2012. pp. 243–78.
46. Lee JH, Kim JM, Kim C. Pharmacokinetic analysis of rhein in Rheum undulatum L. J Ethnopharmacol. 2003;84:5–9. [PubMed]
47. Krumbiegel G, Schulz HU. Rhein and aloe-emodin kinetics from senna laxatives in man. Pharmacology. 1993;47(Suppl 1):120–4. [PubMed]
48. De Witte P. Metabolism and pharmacokinetics of anthranoids. Pharmacology. 1993;1:86–97. [PubMed]
49. Xu F, Liu Y, Zhang Z, Song R, Dong H, Tian Y. Rapid simultaneous quantification of five active constituents in rat plasma by high-performance liquid chromatography/tandem mass spectrometry after oral administration of Da-Cheng-Qi decoction. J Pharm Biomed Anal. 2008;47:586–95. [PubMed]
50. Zhu W, Wang XM, Zhang L, Li XY, Wang BX. Pharmacokinetic of rhein in healthy male volunteers following oral and retention enema administration of rhubarb extract: A single dose study. Am J Chin Med. 2005;33:839–50. [PubMed]
51. Zhang B, Shi Y, Lei TC. Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control. Exp Ther Med. 2012;4:705–10. [PMC free article] [PubMed]
52. Choi RJ, Ngoc TM, Bae K, Cho HJ, Kim DD, Chun J, et al. Anti-inflammatory properties of anthraquinones and their relationship with the regulation of P-glycoprotein function and expression. Eur J Pharm Sci. 2013;48:272–81. [PubMed]
53. Li X, Hu J, Wang B, Sheng L, Liu Z, Yang S, et al. Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: Herb-drug interactions mediated via P-gp. Toxicol Appl Pharmacol. 2014;275:163–75. [PubMed]
54. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom. 2004;18:2273–81. [PubMed]
55. Ma KF, Zhang XG, Jia HY. CYP1A2 polymorphism in Chinese patients with acute liver injury induced by Polygonum multiflorum. Genet Mol Res. 2014;13:5637–43. [PubMed]
56. But PP, Tomlinson B, Lee KL. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum. Vet Hum Toxicol. 1996;38:280–2. [PubMed]
57. Yuen MF, Tam S, Fung J, Wong DK, Wong BC, Lai CL. Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: A 1-year prospective study. Aliment Pharmacol Ther. 2006;24:1179–86. [PubMed]
58. Furukawa M, Kasajima S, Nakamura Y, Shouzushima M, Nagatani N, Takinishi A, et al. Toxic hepatitis induced by show-wu-pian, a Chinese herbal preparation. Intern Med. 2010;49:1537–40. [PubMed]
59. Jung KA, Min HJ, Yoo SS, Kim HJ, Choi SN, Ha CY, et al. Drug-induced liver injury: Twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum Thunb. Gut Liver. 2011;5:493–9.[PMC free article] [PubMed]
60. Dong H, Slain D, Cheng J, Ma W, Liang W. Eighteen cases of liver injury following ingestion of Polygonum multiflorum. Complement Ther Med. 2014;22:70–4. [PubMed]
61. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735–8. [PMC free article] [PubMed]
62. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs. 2001;61:2163–75. [PubMed]
63. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598–604. [PubMed]
64. Sekine I, Saijo N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol. 2001;12:1515–25. [PubMed]
65. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos. 1999;27:180–7. [PubMed]
66. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1–18. [PubMed]
67. Fontana RJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology. 1999;117:89–98. [PubMed]
68. Ashar BH, Dobs AS. Clinical trials for herbal extracts. In: Packer L, Ong CN, Halliwell B, editors. Herbal and Traditional Medicine: Molecular Aspect of Health. New York: Marcel Dekker; 2004. pp. 53–72.
69. Yong EL, Loh YS. Herbal medicines: Criteria for use in health and disease. In: Packer L, Ong CN, Halliwell B, editors. Herbal and Traditional Medicine: Molecular Aspect of Health. New York: Marcel Dekker; 2004. pp. 73–86.
70. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. [PMC free article] [PubMed]
71. Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, et al. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. World J Gastroenterol. 2006;12:3386–92. [PMC free article] [PubMed]
72. Park MY, Kwon HJ, Sung MK. Evaluation of aloin and aloe-emodin as anti-inflammatory agents in aloe by using murine macrophages. Biosci Biotechnol Biochem. 2009;73:828–32. [PubMed]
73. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341–55.[PMC free article] [PubMed]
74. Pan MH, Chiou YS, Tsai ML, Ho CT. Anti-inflammatory activity of traditional Chinese medicinal herbs. J Tradit Complement Med. 2011;1:8–24. [PMC free article] [PubMed]
75. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010;10:369–73.[PubMed]
76. Khatami M. Inflammation, aging, and cancer: Tumoricidal versus tumorigenesis of immunity: A common denominator mapping chronic diseases. Cell Biochem Biophys. 2009;55:55–79. [PubMed]
77. Meng G, Liu Y, Lou C, Yang H. Emodin suppresses lipopolysaccharide-induced pro-inflammatory responses and NF-κB activation by disrupting lipid rafts in CD14-negative endothelial cells. Br J Pharmacol. 2010;161:1628–44. [PMC free article] [PubMed]
78. Weiying L, Yuanjiang D, Baolian L. Treatment of the localized neurodermatitis by plum-blossom needle tapping and with the modified yangxue dingfeng tang - A clinical observation of 47 cases. J Tradit Chin Med. 2006;26:181–3. [PubMed]
79. Tzeng TB, Chang WK, Huang TY, Wu PT, Huang WC, Lee C, et al. Safety and tolerability of physcion in healthy volunteers in a phase I dose escalating clinical pharmacology study. Gastroenterology. 2011;140:S572.
80. Wang M, Zhao R, Wang W, Mao X, Yu J. Lipid regulation effects of Polygoni multiflori Radix, its processed products and its major substances on steatosis human liver cell line L02. J Ethnopharmacol. 2012;139:287–93. [PubMed]
81. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8. [PubMed]
82. Toth PP. Drug treatment of hyperlipidaemia: A guide to the rational use of lipid-lowering drugs. Drugs. 2010;70:1363–79. [PubMed]
83. Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf. 2011;34:1–19. [PubMed]
84. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet. 2010;375:1875–84. [PubMed]
85. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol. 2009;24:372–9. [PubMed]
86. Dou XB, Wo XD, Fan CL. Progress of research in treatment of hyperlipidemia by monomer or compound recipe of Chinese herbal medicine. Chin J Integr Med. 2008;14:71–5. [PubMed]
87. Ke SL, Xie RG, Zheng WR, Xie J. Clinical observation of Polygonum multiflorum in Deqing in treatment of hyperlipidemia. Guang Dong Yi Xue. 2000;21:977–8.
88. Hu M, Zeng W, Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: A randomized, double-blind, placebo-controlled clinical trial. Evid Based Complement Alternat Med. 2014;2014:365742. [PMC free article] [PubMed]
89. Roth T. Insomnia: Definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3:S7–10.[PMC free article] [PubMed]
90. Lamberg L. Several sleep disorders reflect gender differences. Psychiatry News. 2007;42:40.
91. Shi Y, Dong JW, Zhao JH, Tang LN, Zhang JJ. Herbal insomnia medications that target GABAergic systems: A review of the psychopharmacological evidence. Curr Neuropharmacol. 2014;12:289–302.[PMC free article] [PubMed]
92. Petramfar P, Zarshenas MM, Moein M, Mohagheghzadeh A. Management of insomnia in traditional Persian medicine. Forsch Komplementmed. 2014;21:119–25. [PubMed]
93. Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry. 1988;21:447–8. [PubMed]
94. Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: A systematic review and meta-analysis. Am J Med. 2006;119:1005–12. [PMC free article] [PubMed]
95. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26:363–7. [PubMed]
96. Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res. 2011;25:1153–9. [PubMed]
97. Amsterdam JD, Li Y, Soeller I, Rockwell K, Mao JJ, Shults J. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29:378–82. [PMC free article] [PubMed]
98. Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: A randomized placebo-controlled pilot study. BMC Complement Altern Med. 2011;11:78. [PMC free article] [PubMed]
99. Morin CM, Koetter U, Bastien C, Ware JC, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: A randomized placebo-controlled clinical trial. Sleep. 2005;28:1465–71. [PubMed]
100. Koetter U, Schrader E, Käufeler R, Brattström A. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res. 2007;21:847–51. [PubMed]
101. Hartley DE, Elsabagh S, File SE. Gincosan (a combination of Ginkgo biloba and Panax ginseng): The effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women. Nutr Neurosci. 2004;7:325–33. [PubMed]
102. Bradwejn J, Zhou Y, Koszycki D, Shlik J. A double-blind, placebo-controlled study on the effects of Gotu Kola (Centella asiatica) on acoustic startle response in healthy subjects. J Clin Psychopharmacol. 2000;20:680–4. [PubMed]
103. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD) J Altern Complement Med. 2008;14:175–80. [PubMed]
104. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:118–27. [PubMed]
105. Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord. 2004;78:101–10. [PubMed]
106. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res. 2005;19:183–8. [PubMed]
107. Lin Y, Wang XY, Ye R, Hu WH, Sun SC, Jiao HJ, et al. Efficacy and safety of Wuling capsule, a single herbal formula, in Chinese subjects with insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. J Ethnopharmacol. 2013;145:320–7. [PubMed]
108. Baek JH, Nierenberg AA, Kinrys G. Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. Aust N Z J Psychiatry. 2014;48:705–15. [PubMed]
109. Sarris J. Chinese herbal medicine for sleep disorders: Poor methodology restricts any clear conclusion. Sleep Med Rev. 2012;16:493–5. [PubMed]
110. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur Neuropsychopharmacol. 2011;21:841–60. [PubMed]
111. Shen B, Truong J, Helliwell R, Govindaraghavan S, Sucher NJ. An in vitro study of neuroprotective properties of traditional Chinese herbal medicines thought to promote healthy ageing and longevity. BMC Complement Altern Med. 2013;13:373. [PMC free article] [PubMed]
112. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712. [PubMed]
113. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296:1991–5. [PubMed]
114. Krainc D. Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol. 2012;67:388–92. [PubMed]
115. Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8:423–34. [PMC free article] [PubMed]
116. Zhang L, Yu S, Zhang R, Xing Y, Li Y, Li L. Tetrahydroxystilbene glucoside antagonizes age-related a-synuclein overexpression in the hippocampus of APP transgenic mouse model of Alzheimer's disease. Restor Neurol Neurosci. 2013;31:41–52. [PubMed]
117. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao. 1995;16:391–5. [PubMed]
118. Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi. 2002;82:941–4. [PubMed]
119. Chen L, Huang J, Xue L. Effect of compound Polygonum multiflorum extract on Alzheimer's disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:612–5. [PubMed]
120. Li CS, Li J, Guan XH, Wang RX, Wang XX, Yang ZN, et al. Clinical study of Shouwuyizhi capsule in the treatment of vascular dementia. Chin J Geriatr. 2008;28:369–71.
121. Chiu MJ. Efficacy and safety study of DCB-AD1 in patients with mild to moderate Alzheimer's disease. National Taiwan University Hospital Identifier: NCT00154635. 2005
122. Calapai G. Herbal medicines: The European future scene. Evid Based Complement Alternat Med. 2007;4:69–70.
123. Newall CA, Anderson LA, Phillipson JD. A Guide for Health-Care Professionals. 1st ed. 1996. Herbal Medicines; pp. 2–12.
124. Barnes J. Pharmacovigilance of herbal medicines: A UK perspective. Drug Saf. 2003;26:829–51.[PubMed]
125. Teschke R, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: A tabular compilation of reported cases. Liver Int. 2012;32:1543–56. [PubMed]
126. Teschke R, Genthner A, Wolff A, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: Analysis of cases with initially reported positive re-exposure tests. Dig Liver Dis. 2014;46:264–9. [PubMed]
127. Laird AR, Ramchandani N, deGoma EM, Avula B, Khan IA, Gesundheit N. Acute hepatitis associated with the use of an herbal supplement (Polygonum multiflorum) mimicking iron-overload syndrome. J Clin Gastroenterol. 2008;42:861–2. [PubMed]
128. Wang GQ, Deng YQ, Hou FQ. Overview of drug-induced liver injury in China. Clin Liver Dis. 2014;4:26–9.
129. Banarova A, Koller T, Payer J. Toxic hepatitis induced by Polygonum multiflorum. Vnitr Lek. 2012;58:958–62. [PubMed]
130. Wu X, Chen X, Huang Q, Fang D, Li G, Zhang G. Toxicity of raw and processed roots of Polygonum multiflorum. Fitoterapia. 2012;83:469–75. [PubMed]
131. Obodozie OO. Pharmacokinetics and drug interactions of herbal medicines: A missing critical step in the phytomedicine/drug development process. In: Noreddin A, editor. Reading in Advanced Pharmacokinetics - Theory, Methods, and Applications. Croatia: InTech; 2012. pp. 127–56.
132. Williamson E, Driver S, Baxter K. Stockley's Herbal Medicines Interactions. London: Pharmaceutical Press; 2009. pp. 1–10.
133. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: Analysis of the 2002 national health interview survey data. Arch Intern Med. 2006;166:1775–82.[PubMed]